Expanding Substance Use Treatment Options for HIV Prevention With Buprenorphine–Naloxone
David S. Metzger(California University of Pennsylvania), David Burns(Norwegian Womens Public Health Association), Ray Y. Chen(National Institute of Allergy and Infectious Diseases), Yuhua Ruan(Chinese Center For Disease Control and Prevention), Gregory M. Lucas(Johns Hopkins University), Katherine Shin, Marek C. Chawarski(Johns Hopkins University), Bonnie J. Dye(Family Health International 360), Jeremy Sugarman(Johns Hopkins Berman Institute of Bioethics), David D. Celentano(Johns Hopkins University), Apinun Aramrattana(Chiang Mai University), Geetha Beauchamp(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Paul Richardson(University of Liverpool), Deborah Donnell(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Jun Ma(Peking University), Yiming Shao(Guangdong Medical College), Liu Wei(Guangxi Center for Disease Prevention and Control), J. Brooks Jackson(VA Tennessee Valley Healthcare System), Scott M. Rose(Family Health International 360), Liping Fu(Xinjiang Uygur Autonomous Region Disease Prevention and Control Center)
Cited by 34
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
|New England Journal of Medicine|2012|3.3k
Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults
|The Lancet|2024|2.2k
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|New England Journal of Medicine|2016|1.7k